Hikma Pharmaceuticals PLC announced that Health Canada has approved KLOXXADO (naloxone HCl) Nasal Spray 8 mg for the treatment of known or suspected opioid overdose in adult patients. KLOXXADO delivers 8 mg of naloxone hydrochloride per spray, offering a ready-to-use nasal spray option.
Emergent BioSolutions will market and sell KLOXXADO in Canada under a recent six-year commercial agreement with Hikma, making Emergent responsible for all North American product sales and marketing. Hikma will continue to produce KLOXXADO Nasal Spray at its Columbus, Ohio manufacturing facility.
Following this approval, Emergent plans to engage Canadian agencies, private payers, and provincial formularies, with the aim of making KLOXXADO available via prescription as early as 2026. This addition complements NARCAN Nasal Spray, providing a higher-dose naloxone option to help address the opioid crisis in Canada.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.